I had a routine blood test and doctor visit yesterday and learned from him that Tasigna was approved on June 20 by US FDA for newly diagnosed CML patients. Formerly, Tasigna had been approved only for CML patients who were intolerant or failing Gleevec. This is a link to an article on the announcement which was made at the ASCO annual meeting. http://www.medscape....warticle/723893
This is a link to Jerry Mayfield's bbs discussing Tasigna - http://www.newcmldru...6078&Reply=6078
Ongoing Phase 3 Safety and Efficacy clinical trial in comparison with Imatinib results are very encouraging.
I also learned that my high blood glucose may be a side effect of Tasigna. It is not (yet) high enough to be acutely dangerous, but I need to get it under control - which means diet and exercise.
When I went to get my Rx filled, I learned that Tasigna is batch-made (apparently, only one batch per year!) and that the current batch carries an expiration date in November. Novartis will no doubt be on time with next year's batch, but it may mean that some prescriptions will be partially filled between now and November. The usual practice for the pharmacist is to hold the Rx open in their files, (since they can't dispense medication to a patient that will expire before it is taken), then contact the patient when the unfilled quantity becomes available. I'd suggest keeping this sort of thing in mind when getting a Tasigna Rx filled since the insurance companys' policies on this may mean obtaining a new prescription for the portion unfilled by the original prescription.
I began taking Tasigna July 21, 2007 as a participant in the Phase 2 clinical trial when it was still called AMN107. I was dx'd on 7/18/07 in accelerated phase CML. I was well enough to return to work only 3 weeks later, although my company didn't allow me to do so for six weeks.
Doug










